<DOC>
	<DOCNO>NCT01339572</DOCNO>
	<brief_summary>This protocol investigate effectiveness plerixafor up-front set avoid second round mobilization whether translates clinical economic benefit .</brief_summary>
	<brief_title>Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation</brief_title>
	<detailed_description>Peripheral blood stem cell consider standard source stem cell autologous stem cell transplant . Unfortunately , still 20-30 % chance inadequate number stem cell collect , result prolonged recovery cell count transplantation increase transfusion dependence . There also significant economic burden associate remobilization risk delay collect sufficient number stem cell result increase chance disease recurrence prior transplantation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients multiple myeloma nonHodgkin 's lymphoma plan autologous transplant eligible peripheral stem cell mobilization . Karnofsky Performance Status ≥ 70 . Age ≥ 18 Less 30 % involvement marrow disease . &gt; 30 % marrow involvement disease Age &lt; 18 . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>autologous transplantation</keyword>
	<keyword>peripheral stem cell mobilization</keyword>
</DOC>